ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Inflammation Disrupts Memory - What Can You Do to Protect Your Brain?

All About Ginkgo Biloba: Benefits of This Timeless Herbal Supplement

Yarrow Oil: Here's Why It Deserves a Place in Your First-Aid Kit

Artificial sweeteners linked to risk of weight gain, heart disease and other health issues

Vitamin D supplement use associated with lower risk of breast cancer

Carnitine deficiency suggested as contributor to autism

Hop Oil: A Safe Sleep Aide

Lutein — An Important Nutrient for Eye and Brain Health

White Camphor Oil: The Purest Camphor Oil

Taurine: Facts About This Crucial Amino Acid

 
Print Page
Email Article

Potential Anti-Cancer Agent Being Developed from Anti-Inflammation Drug

  [ 20 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 8, 2004


Source: Cancer Research (journal) COLUMBUS, Ohio – Researchers have used a recently developed anti-inflammatory drug as a starting point to construct a possible new, targeted anti-cancer agent. The new agent works by triggering cancer cells to self-destruct. The agent is now undergoing laboratory testing by the National Cancer Institute’s (NCI) Rapid Access to Intervention Development (RAID) program. The potential new drug was developed by researchers at The Ohio State University College of Pharmacy and the OSU Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Presently, the agent is known as OSU-03012. The study is published in the June 15 issue of the journal Cancer Research. “This new agent works by inhibiting a fundamental signaling point in cancer cells, making it potentially effective in a wide range of cancer types,” says study leader Ching-Shih Chen, professor of pharmacy and a researcher with OSU’s Comprehensive Cancer Center. “We also have evidence that it may sensitize leukemia, and breast and lung cancers to conventional chemotherapy.” The new agent is based on the drug celecoxib, a nonsteroidal anti-inflammatory drug, or NSAID. Like many NSAIDs, celecoxib also reduces the risk of colorectal cancer when taken regularly. Scientists knew from the start that celecoxib helps control inflammation by inhibiting an enzyme known as cyclooxygenase-2 (COX-2). But they couldn’t explain the drug’s modest anti-cancer activity. Past work led by Chen provided the answer. “We found that celecoxib’s ability to cause cell death and to control inflammation were two different pharmacological properties, and that the two properties could be separated,” Chen says. This work was published in the Journal of the National Cancer Institute. Chen and his colleagues then showed that celecoxib inhibited a molecule known as Akt. Chen describes Akt as an important molecular switch that transmits information from the cell surface down into the cell to interact with a variety of target molecules. He and colleagues further found that the blocking of Akt by celecoxib in cancer cells triggered programmed cell death, a process also known as apoptosis. For this study, Chen and his colleagues used molecular-modeling methods and computational chemistry to alter celecoxib’s basic molecular structure in ways calculated to maximize its Akt-blocking and cell-death inducing activities. This work generated a series of derivative molecules, all of which were far different in structure from celecoxib. Two of these proved to be 30 to 50 times more potent than celecoxib in inducing programmed cell death in cancer cells growing in the laboratory tests. One of the derivatives, OSU 03012, is now undergoing toxicological and pharmacological testing by the NCI’s RAID program. Data from these tests will help move the agent forward into human testing in a phase I clinical trial, probably within one to two years. Funding from the National Cancer Institute and the Department of Defense Prostate Cancer Research Program supported this research. Source: EurekAlert.org (this is a press release).



Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map